Overall survival · people with advanced gastric cancer
Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).
1 finding from 1 review
Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer
Docetaxel showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Overall survival ‐ Other comparisons · people with advanced gastric cancer
It is very uncertain whether docetaxel changes overall survival ‐ Other comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
1 finding from 1 review
Tumour response · people with advanced gastric cancer
Docetaxel probably leads to higher tumour response compared with non‐docetaxel‐containing regimens (moderate certainty).
4 findings from 1 review
OR 1.37 [1.03, 1.83]
9 studies · 1820 participants
Moderate
OR 1.03 [0.71, 1.5]
4 studies · 525 participants
Moderate
OR 1.83 [1.45, 2.32]
4 studies · 1235 participants
High
Show 1 more finding
Time to progression · people with advanced gastric cancer
It is very uncertain whether docetaxel changes time to progression compared with non‐docetaxel‐containing regimens (very low certainty).
1 finding from 1 review
Progression‐free survival · people with advanced gastric cancer
Docetaxel probably leads to lower progression‐free survival compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · people with advanced gastric cancer
It is very uncertain whether docetaxel changes progression‐free survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (very low certainty).
3 findings from 1 review
HR 1.15 [0.77, 1.72]
1 study · 119 participants
Very low
HR 0.7 [0.61, 0.81]
3 studies · 1323 participants
High
HR 0.94 [0.55, 1.6]
1 study · 56 participants
Very low
Treatment‐related death · people with advanced gastric cancer
Docetaxel showed no clear difference in treatment‐related death compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
Treatment discontinuation due to toxicity · people with advanced gastric cancer
Docetaxel showed no clear difference in treatment discontinuation due to toxicity compared with non‐docetaxel‐containing regimens (low certainty).
1 finding from 1 review
Irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir, epirubicin, multiple drugsϯ · healthcare staff who handle infusional hazardous drugs
It is very uncertain whether closed‐system transfer device plus safe handling changes irinotecan, docetaxel, paclitaxel, vinorelbine, ganciclovir,… compared with safe handling alone (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
5‐fluorouracil, cytarabine, gemcitabine, irinotecan, docetaxel, paclitaxel, vinorelbine, multiple drugsϯ · healthcare staff who handle infusional hazardous drugs
1 finding from 1 review
no estimate extracted
Studies not reported
Very low